T. Rowe Price Associates
FOLD

T. Rowe Price Associates’s Amicus Therapeutics FOLD Stock Holding History

T. Rowe Price Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.91M Buy
339,363
+57,521
+20% +$825K ﹤0.01% 1427
2025
Q4 		$4.01M Sell
281,842
-774,019
-73% -$7.6M ﹤0.01% 1474
2025
Q3 		$8.32M Buy
1,055,861
+9,646
+0.9% +$68.7K ﹤0.01% 1271
2025
Q2 		$6M Sell
1,046,215
-236,851
-18% -$1.53M ﹤0.01% 1227
2025
Q1 		$10.5M Sell
1,283,066
-85,575
-6% -$792K ﹤0.01% 1110
2024
Q4 		$12.9M Buy
1,368,641
+26,720
+2% +$278K ﹤0.01% 1097
2024
Q3 		$14.3M Sell
1,341,921
-48,126
-3% -$524K ﹤0.01% 1065
2024
Q2 		$13.8M Buy
1,390,047
+686
+0% +$7.04K ﹤0.01% 1046
2024
Q1 		$16.4M Buy
1,389,361
+12,003
+0.9% +$154K ﹤0.01% 1024
2023
Q4 		$19.5M Sell
1,377,358
-19,737
-1% -$224K ﹤0.01% 962
2023
Q3 		$17M Buy
1,397,095
+4,481
+0.3% +$57.8K ﹤0.01% 955
2023
Q2 		$17.5M Sell
1,392,614
-76,388
-5% -$906K ﹤0.01% 970
2023
Q1 		$16.3M Sell
1,469,002
-21,193
-1% -$261K ﹤0.01% 971
2022
Q4 		$18.2M Buy
1,490,195
+31,475
+2% +$354K ﹤0.01% 935
2022
Q3 		$15.2M Sell
1,458,720
-7,275
-0.5% -$81.1K ﹤0.01% 986
2022
Q2 		$15.7M Buy
1,465,995
+4,864
+0.3% +$40.1K ﹤0.01% 1230
2022
Q1 		$13.8M Sell
1,461,131
-604,011
-29% -$5.66M ﹤0.01% 1319
2021
Q4 		$23.9M Sell
2,065,142
-712,106
-26% -$7.94M ﹤0.01% 1244
2021
Q3 		$26.5M Buy
2,777,248
+209,572
+8% +$2.14M ﹤0.01% 1224
2021
Q2 		$24.8M Buy
2,567,676
+482,004
+23% +$4.7M ﹤0.01% 1250
2021
Q1 		$20.6M Buy
2,085,672
+36,310
+2% +$562K ﹤0.01% 1271
2020
Q4 		$47.3M Buy
2,049,362
+858,025
+72% +$17.5M ﹤0.01% 980
2020
Q3 		$16.8M Buy
1,191,337
+70,084
+6% +$1.02M ﹤0.01% 1194
2020
Q2 		$16.9M Buy
1,121,253
+171,408
+18% +$2.09M ﹤0.01% 1186
2020
Q1 		$8.78M Buy
949,845
+6,198
+0.7% +$58.9K ﹤0.01% 1251
2019
Q4 		$9.19M Buy
943,647
+83,870
+10% +$768K ﹤0.01% 1321
2019
Q3 		$6.89M Sell
859,777
-4,804
-0.6% -$52.1K ﹤0.01% 1342
2019
Q2 		$10.8M Buy
864,581
+1,236
+0.1% +$15.7K ﹤0.01% 1302
2019
Q1 		$11.7M Sell
863,345
-1,932
-0.2% -$23.6K ﹤0.01% 1294
2018
Q4 		$8.29M Sell
865,277
-1,623,357
-65% -$17.8M ﹤0.01% 1334
2018
Q3 		$30.1M Sell
2,488,634
-3,427,311
-58% -$47.9M ﹤0.01% 1089
2018
Q2 		$92.4M Buy
5,915,945
+966,312
+20% +$14.6M 0.01% 685
2018
Q1 		$74.4M Sell
4,949,633
-4,113,678
-45% -$62.6M 0.01% 729
2017
Q4 		$130M Buy
9,063,311
+971,280
+12% +$13.3M 0.02% 567
2017
Q3 		$122M Buy
8,092,031
+5,277,190
+187% +$69.8M 0.02% 574
2017
Q2 		$28.3M Sell
2,814,841
-26,989
-0.9% -$217K 0.01% 1043
2017
Q1 		$20.3M Sell
2,841,830
-200,100
-7% -$1.27M ﹤0.01% 1156
2016
Q4 		$15.1M Sell
3,041,930
-1,297,405
-30% -$8.98M ﹤0.01% 1223
2016
Q3 		$32.1M Sell
4,339,335
-1,544,613
-26% -$10.4M 0.01% 959
2016
Q2 		$32.1M Sell
5,883,948
-17,100
-0.3% -$120K 0.01% 933
2016
Q1 		$49.9M Sell
5,901,048
-28,020
-0.5% -$198K 0.01% 770
2015
Q4 		$57.5M Buy
5,929,068
+41,103
+0.7% +$370K 0.01% 714
2015
Q3 		$82.4M Buy
5,887,965
+63,665
+1% +$998K 0.02% 621
2015
Q2 		$82.4M Buy
5,824,300
+5,203,051
+838% +$62.6M 0.02% 663
2015
Q1 		$6.76M Buy
+621,249
New +$5.48M ﹤0.01% 1423

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates's FOLD Position: Q1 2026 in Review

T. Rowe Price Associates increased its Amicus Therapeutics (FOLD) stake by 20% in Q1 2026, buying an estimated $825K and bringing the position to 339,363 shares worth $4.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1427.

T. Rowe Price Associates first reported a position in FOLD in Q1 2015 and has held it in 45 quarters since. The position peaked at $130M in Q4 2017. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • T. Rowe Price Associates held 339,363 shares of Amicus Therapeutics worth $4.91M as of Q1 2026.
  • T. Rowe Price Associates bought 57,521 Amicus Therapeutics shares in Q1 2026, an estimated $825K.
  • Amicus Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1427 holding.
  • T. Rowe Price Associates first reported a position in Amicus Therapeutics in Q1 2015 and has held it in 45 quarters since.
  • T. Rowe Price Associates's Amicus Therapeutics position peaked at $130M in Q4 2017.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.